Patents Assigned to Evestra, Inc.
  • Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
    Patent number: 10738075
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: August 11, 2020
    Assignee: Evestra, Inc.
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Longer-acting progestin prodrug contraceptives
    Patent number: 10624903
    Abstract: Described herein are progestin compounds that have extended release rates and that can be used without an estrogen to produce a contraceptive state.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: April 21, 2020
    Assignee: Evestra, Inc.
    Inventors: Gulzar Ahmed, Frederick Meece, Hareesh Nair, Klaus Nickisch
  • Pro-drug forming compounds
    Patent number: 10273263
    Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 30, 2019
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
    Patent number: 10053485
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: August 21, 2018
    Assignee: Evestra, Inc.
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
    Patent number: 9850273
    Abstract: Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 26, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Hareesh Nair, Walter Elger
  • Pro-drug forming compounds
    Patent number: 9745338
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 29, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Imidazolyl progesterone antagonists
    Patent number: 9096641
    Abstract: Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: August 4, 2015
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Walter Elger, Bindu Santhamma
  • Progesterone antagonists
    Patent number: 8673968
    Abstract: Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: March 18, 2014
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, James Cessac, Kesavaram Narkunan, Baishakhi Das
  • Methods for the preparation of drospirenone
    Patent number: 8334375
    Abstract: Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: December 18, 2012
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Kirk Acosta, Bindu Santhamma
  • Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones
    Patent number: 8222237
    Abstract: Described herein are 3-(6,6-ethylene-17?-hydroxy-3-oxo-17?-pregna-4-ene-17?-yl)propionic acid ?-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 17, 2012
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Pemmaraju Rao, Kesavaram Narkunan, James Cessac